Tuesday, September 24, 2024
HomeTagsImmuneOncia

ImmuneOncia

WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody

WuXi Biologics, a global company with leading open-access biologics technology platforms, and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, announced that...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics